Literature DB >> 24521857

Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.

Noriko Kimura, Ryoichi Takayanagi, Nae Takizawa, Eiji Itagaki, Takayuki Katabami, Narihiko Kakoi, Hiromi Rakugi, Yukihiro Ikeda, Akiyo Tanabe, Takeshi Nigawara, Sadayoshi Ito, Itaru Kimura, Mitsuhide Naruse.   

Abstract

Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological markers predicting metastasis are urgently required. A total of 163 tumours, including 40 metastatic tumours, collected by the Phaeochromocytoma Study Group in Japan (PHEO-J) were analysed using a system called grading system for adrenal phaeochromocytoma and paraganglioma (GAPP). The tumours were scored based on GAPP criteria as follows: histological pattern, cellularity, comedo-type necrosis, capsular/vascular invasion, Ki67 labelling index and catecholamine type. All tumours were scored from 0 to 10 points and were graded as one of the three types: well-differentiated (WD, 0-2 points), moderately differentiated (MD, 3-6 points) and poorly differentiated (PD, 7-10 points). GAPP scores of the non-metastatic and metastatic groups were 2.08±0.17 and 5.33±0.43 (mean±s.e.m., P<0.001) respectively. There was a significant negative correlation between the GAPP score and the interval until metastasis (r=-0.438, P<0.01). The mean number of years until metastasis after the initial operation was 5.5±2.6 years. The study included 111 WD, 35 MD and 17 PD types. The five-year survival of these groups was 100, 66.8 and 22.4% respectively. In addition, negative immunoreactivity for succinate dehydrogenase gene subunit B (SDHB) was observed in 13 (8%) MD or PD tumours and ten of the 13 (77%) had metastases. Our data indicate that a combination of GAPP classification and SDHB immunohistochemistry might be useful for the prediction of metastasis in these tumours.

Entities:  

Keywords:  histopathological diagnosis; immunohistochemistry; metastasis; paraganglioma; phaeochromocytoma; succinate dehydrogenase gene subunit B; survival

Mesh:

Substances:

Year:  2014        PMID: 24521857     DOI: 10.1530/ERC-13-0494

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  80 in total

1.  Neuroendocrine cancer. Closing the GAPP on predicting metastases.

Authors:  Graeme Eisenhofer; Arthur S Tischler
Journal:  Nat Rev Endocrinol       Date:  2014-04-01       Impact factor: 43.330

2.  SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).

Authors:  Thomas G Papathomas; Lindsey Oudijk; Alexandre Persu; Anthony J Gill; Francien van Nederveen; Arthur S Tischler; Frédérique Tissier; Marco Volante; Xavier Matias-Guiu; Marcel Smid; Judith Favier; Elena Rapizzi; Rosella Libe; Maria Currás-Freixes; Selda Aydin; Thanh Huynh; Urs Lichtenauer; Anouk van Berkel; Letizia Canu; Rita Domingues; Roderick J Clifton-Bligh; Magdalena Bialas; Miikka Vikkula; Gustavo Baretton; Mauro Papotti; Gabriella Nesi; Cécile Badoual; Karel Pacak; Graeme Eisenhofer; Henri J Timmers; Felix Beuschlein; Jérôme Bertherat; Massimo Mannelli; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Winand Nm Dinjens; Esther Korpershoek; Ronald R de Krijger
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

3.  Recurrent, bilateral, and metastatic pheochromocytoma in a young patient with Beckwith-Wiedemann syndrome: A genetic link?

Authors:  Tiffany Caza; Jared Manwaring; Jonathan Riddell
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

4.  Malignant Intrarenal/Renal Pelvis Paraganglioma with Co-Occurring SDHB and ATRX Mutations.

Authors:  Trent Irwin; Eric Q Konnick; Maria S Tretiakova
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

5.  Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.

Authors:  Joakim Crona; Angela Lamarca; Suman Ghosal; Staffan Welin; Britt Skogseid; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-05       Impact factor: 5.678

6.  Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.

Authors:  Sounak Gupta; Jun Zhang; Lori A Erickson
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

7.  Dopamine-Secreting Paraganglioma in the Retroperitoneum.

Authors:  Yusuke Matsuda; Noriko Kimura; Takanobu Yoshimoto; Yoshihiro Sekiguchi; Junzo Tomoishi; Ichiro Kasahara; Yoshihito Hara; Yoshihiro Ogawa
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 8.  Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Authors:  Alfred King-Yin Lam
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

9.  In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma.

Authors:  Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Marc Cartellieri; Nan Qin; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Jens Pietzsch; Graeme Eisenhofer; Stefan R Bornstein; Christian G Ziegler
Journal:  Endocrinology       Date:  2014-08-19       Impact factor: 4.736

10.  N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.

Authors:  Helena Leijon; Tuomas Kaprio; Annamari Heiskanen; Tero Satomaa; Jukka O Hiltunen; Markku M Miettinen; Johanna Arola; Caj Haglund
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.